

DAFTAR PUSTAKA

- Allen, E. S. (2002) 'The Liver : Anatomy , Physiology , Disease and Treatment', *Human Anatomy & Physiology*, pp. 3–11.
- Almeda-Valdés, P., Cuevas-Ramos, D. and Aguilar-Salinas, C. A. (2009) 'Metabolic syndrome and non-alcoholic fatty liver disease.', *Annals of Hepatology*, 8(Suppl 1), pp. S18–S24.
- Amarapurkar, D. N. *et al.* (2007) 'How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences?', *Journal of Gastroenterology and Hepatology (Australia)*, 22(6), pp. 788–793. doi: 10.1111/j.1440-1746.2007.05042.x.
- Angulo, P. (2002) 'N f l d', 346(16), pp. 1221–1231.
- Aniel, D. *et al.* (2000) 'E Valuation of a Bnormal L Iver -E Nzyme R Esults in a Symptomatic P Atients'.
- Atmaca, G. (2004) 'Antioxidant effects of sulfur-containing amino acids', *Yonsei Medical Journal*, pp. 776–788. doi: 200410776 [pii].
- Bellentani, S. *et al.* (2010) 'Epidemiology of non-alcoholic fatty liver disease', *Digestive Diseases*, 28(1), pp. 155–161. doi: 10.1159/000282080.
- Bellentani, S. and Marino, M. (2009) 'Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)', *Annals of Hepatology*, 8(1), pp. s4–s8. doi: 10.1016/j.metabol.2016.01.012.
- Brown, M. S. and Goldstein, J. L. (2008) 'Selective versus Total Insulin Resistance: A Pathogenic Paradox', *Cell Metabolism*, 7(2), pp. 95–96. doi: 10.1016/j.cmet.2007.12.009.
- Campbell, M. S. and Reddy, K. R. (2004) 'Review article: The evolving role of liver biopsy', *Alimentary Pharmacology and Therapeutics*, 20(3), pp. 249–259. doi: 10.1111/j.1365-2036.2004.02071.x.
- Chitturi, S., Farrell, G. C. and George, J. (2004) 'Non-alcoholic steatohepatitis in the Asia-Pacific region: Future shock?', *Journal of Gastroenterology and Hepatology (Australia)*, 19(4), pp. 368–374. doi: 10.1111/j.1440-1746.2003.03252.x.
- Clark, J. M., Brancati, F. L. and Diehl, A. M. (2002) 'Nonalcoholic fatty liver disease', *Gastroenterology*, 122(6), pp. 1649–1657. doi: 10.1016/j.bpg.2010.08.005.
- Cortez-Pinto, H. and Camilo, M. E. (2004) 'Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): Diagnosis and clinical course', *Best Practice and Research: Clinical Gastroenterology*, 18(6 SPEC.ISS.), pp. 1089–1104. doi: 10.1016/j.bpg.2004.06.021.
- Dyson, J. K., Anstee, Q. M. and McPherson, S. (2015) 'Republished: Non-alcoholic fatty liver disease: a practical approach to treatment', *Postgraduate Medical Journal*, 91(1072), pp. 92–101. doi: 10.1136/postgradmedj-2013-100404rep.
- Esterbauer, H., Schaur, R. J. and Zollner, H. (1991) 'Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes', *Free Radical Biology and Medicine*, 11(1), pp. 81–128. doi: 10.1016/0891-5849(91)90192-6.
- Ferramosca, A., Di Giacomo, M. and Zara, V. (2017) 'Antioxidant dietary approach in treatment of fatty liver: New insights and updates', *World Journal of Gastroenterology*, 23(23), pp. 4146–4157. doi: 10.3748/wjg.v23.i23.4146.

- Forouhi, N. G. *et al.* (2018) 'Dietary fat and cardiometabolic health : evidence, controversies, and consensus for guidance and colleagues', *British Medical Journal*, 2139(June), pp. 1–8. doi: 10.1136/bmj.k2139.
- Gorąca, A. *et al.* (2011) 'Lipoic acid - biological activity and therapeutic potential.', *Pharmacological reports: PR*, 63(4), pp. 849–58. doi: 10.1016/S1734-1140(11)70600-4.
- Hermanto, S., Muawanah, A. and Harahap, R. (2008) 'Profil dan karakteristik lemak hewani (ayam, sapi, dan babi) hasil analisis FTIR dan GCMS', *Jurnal Kimia Valensi*, 1(3), pp. 102–109. doi: 10.15408/JKV.V1I3.219.
- Horton, J. D. (2002) 'Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis.', *Biochemical Society transactions*, 30, pp. 1091–1095. doi: 10.1042/.
- Hübscher, S. G. (2006) 'Histological assessment of non-alcoholic fatty liver disease', *Histopathology*, 49(5), pp. 450–465. doi: 10.1111/j.1365-2559.2006.02416.x.
- Ipsen, D. H., Tveden-nyborg, P. and Lykkesfeldt, J. (2016) 'Dyslipidemia : Obese or Not Obese — That Is Not the Question', *Current Obesity Reports*. Current Obesity Reports, pp. 405–412. doi: 10.1007/s13679-016-0232-9.
- Jung, T. S. *et al.* (2012) 'α-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats', (11), pp. 1–9. doi: 10.1111/j.1478-3231.2012.02857.x.
- Kammoun, H. L. *et al.* (2009) 'GR 78 e resion inhibits insulin and ER stress induced REB 1c acti ation and reduces he atic steatosis in mice', *The Journal of Clinical investigation*, 119(5), pp. 1201–1215. doi: 10.1172/JCI37007DS1.
- Kim, M. S. *et al.* (2004) 'Anti-obesity effects of α-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase', *Nature Medicine*, 10(7), pp. 727–733. doi: 10.1038/nm1061.
- Kleiner, D. E. *et al.* (2005) 'Design and validation of a histological scoring system for nonalcoholic fatty liver disease', *Hepatology*, 41(6), pp. 1313–1321. doi: 10.1002/hep.20701.
- Kobayashi, M. *et al.* (2018) 'SREBP-1c-Dependent Metabolic Remodeling of White Adipose Tissue by Caloric Restriction', *International Journal of Molecular Sciences*, pp. 1–11. doi: 10.3390/ijms19113335.
- Kwiecień, B. and Dudek, M. (2013) 'In Vivo Anti-inflammatory Activity of Lipoic Acid Derivatives in Mice * Aktywność przeciwzapalna pochodnych kwasu liponowego w badaniach in vivo u myszy', (2335), pp. 331–338. doi: 10.5604/17322693.1046290.
- Lewis, J. R. and Mohanty, S. R. (2010) 'Nonalcoholic fatty liver disease: A review and update', *Digestive Diseases and Sciences*, 55(3), pp. 560–578. doi: 10.1007/s10620-009-1081-0.
- Li, Y. *et al.* (2004) 'Scavenging ability on ROS of alpha-lipoic acid (ALA)', *Food Chemistry*, 84(4), pp. 563–567. doi: 10.1016/S0308-8146(03)00279-6.
- Liang, W. *et al.* (2014) 'Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology', *PLoS ONE*, pp. 1–17. doi: 10.1371/journal.pone.0115922.
- Marceau, P. *et al.* (1999) 'Liver Pathology and the Metabolic Syndrome X in Severe Obesity', *The Journal of Clinical Endocrinology & Metabolism*, 84(5), pp. 1513–1517. doi: 10.1210/jcem.84.5.5661.
- Marchesini, G. *et al.* (2001) 'Nonalcoholic fatty liver disease: A feature of the

- metabolic syndrome', *Diabetes*, 50(8), pp. 1844–1850. doi: 10.1097/MOG.000000000000175.
- Min, A. K. *et al.* (2012) 'Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice', *Life Sciences*. Elsevier Inc., 90(5–6), pp. 200–205. doi: 10.1016/j.lfs.2011.11.012.
- Mofrad, P. *et al.* (2003) 'Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values', *Hepatology*, 37(6), pp. 1286–1292. doi: 10.1053/jhep.2003.50229.
- Moss, S. E., Klein, R. and Klein, B. E. (1991) 'Cause-specific mortality in a population-based study of diabetes.', *American Journal of Public Health*, 81(9), pp. 1158–1162. doi: 10.2105/AJPH.81.9.1158.
- Naik, A. and Belic, A. (2012) 'Modelling Metabolic Pathways Involved in the Pathogenesis of Non-Alcoholic Fatty Liver Disease', *Mathmod 2012*, 7(1). doi: 10.3182/20120215-3-AT-3016.00161.
- Ozougwu, J. C. and Eyo, J. E. (2014) 'Hepatoprotective effects of Allium cepa (onion) extracts against paracetamol-induced liver damage in rats', *African Journal of Biotechnology*, 13(26), pp. 2679–2688. doi: 10.5897/AJB2014.13815.
- Petta, S., Muratore, C. and Craxì, A. (2009) 'Non-alcoholic fatty liver disease pathogenesis: The present and the future', *Digestive and Liver Disease*, 41(9), pp. 615–625. doi: 10.1016/j.dld.2009.01.004.
- Poynard, T. *et al.* (2005) 'The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis', *Comparative Hepatology*, 4, pp. 1–14. doi: 10.1186/1476-5926-4-10.
- Prasanna K. Santhekadur, D. P. K. and A. J. S. (2019) 'Preclinical Models of Nonalcoholic Fatty Liver Disease', *Journal of Hepatology*, 68(2), pp. 230–237. doi: 10.1016/j.jhep.2017.10.031.PRECLINICAL.
- Ratziu, V. *et al.* (2006) 'Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease', *BMC Gastroenterology*, 6(1), p. 6. doi: 10.1186/1471-230X-6-6.
- Rector, R. S. *et al.* (2008) 'Non-alcoholic fatty liver disease and the metabolic syndrome: an update.', *World journal of gastroenterology : WJG*, 14(2), pp. 185–192. doi: 10.3748/wjg.14.185.
- Rector, R. S. *et al.* (2011) 'Daily exercise vs . caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model', *The American Journal of Physiology-Gastrointestinal and Liver Physiology*, pp. 874–883. doi: 10.1152/ajpgi.00510.2010.
- Rolls, B. J. (2014) 'The relationship between dietary energy density and energyintake', *Physiology Behavior*, 97(5), pp. 609–615. doi: 10.1016/j.physbeh.2009.03.011.The.
- Salt, W. B. (2004) 'Nonalcoholic Fatty Liver Disease (NAFLD): A Comprehensive Review', *Journal of Insurance Me*, 36(1), pp. 27–41.
- Schwenger, K. J. P. and Allard, J. P. (2014) 'Clinical approaches to non-alcoholic fatty liver disease', *World Journal of Gastroenterology*, 20(7), pp. 1712–1723. doi: 10.3748/wjg.v20.i7.1712.
- Seo, E. Y., Ha, A. W. and Kim, W. K. (2012) 'α -Lipoic acid reduced weight gain and improved the lipid profile in rats fed with high fat diet', *Nutrition*

- Research and Practice*, 6(2009), pp. 195–200.
- Shay, K., Moreau, R. and Smith, E. (2009) ‘Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential’, *Biochimica et Biophysica ...*, 1790(10), pp. 1149–1160. doi: 10.1016/j.bbagen.2009.07.026.Alpha-lipoic.
- Singh, U. and Jialal, I. (2008) ‘Alpha-lipoic acid supplementation and diabetes’, *Nutrition Reviews*, 66(11), pp. 646–657. doi: 10.1111/j.1753-4887.2008.00118.x.
- Tonukari, N. J. (2012) ‘African Journal of’, 11(2), pp. 133–140.
- Valdecantos, M. P. *et al.* (2012) ‘Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function’, *Journal of Nutritional Biochemistry*. Elsevier Inc., 23(12), pp. 1676–1684. doi: 10.1016/j.jnutbio.2011.11.011.
- Wallace, K., Burt, A. D. and Wright, M. C. (2008) ‘Liver fibrosis’, *Biochemical Journal*, 411(1), pp. 1–18. doi: 10.1042/BJ20071570.
- Zha, B. S. and Zhou, H. (2012) ‘ER stress and lipid metabolism in adipocytes’, *Biochemistry Research International*, 2012. doi: 10.1155/2012/312943.
- Zhou, E. and Lucas, K. B. (2018) ‘Alpha-Lipoic Acid (ALA) as a supplementation for weight loss: Results from a Meta-Analysis of Randomized Controlled Trials’, *Obesity Reviews*, 18(5), pp. 594–601. doi: 10.1111/obr.12528.Alpha-Lipoic.
- Zulkhairi, A. *et al.* (2008) ‘Lipid lowering effect of antioxidant alpha-lipoic Acid in experimental atherosclerosis.’, *Journal of clinical biochemistry and nutrition*, 43(2), pp. 88–94. doi: 10.3164/jcbtn.2008051.